Sterling Capital Management LLC Buys 4,424 Shares of Halozyme Therapeutics, Inc. $HALO

Sterling Capital Management LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 570.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,199 shares of the biopharmaceutical company’s stock after acquiring an additional 4,424 shares during the quarter. Sterling Capital Management LLC’s holdings in Halozyme Therapeutics were worth $574,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. James Investment Research Inc. lifted its holdings in Halozyme Therapeutics by 10.8% during the 3rd quarter. James Investment Research Inc. now owns 29,436 shares of the biopharmaceutical company’s stock worth $3,250,000 after purchasing an additional 2,858 shares during the last quarter. Inspire Investing LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at $3,129,000. Root Financial Partners LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at $82,000. SBI Securities Co. Ltd. boosted its stake in Halozyme Therapeutics by 78.2% in the 3rd quarter. SBI Securities Co. Ltd. now owns 898 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 394 shares during the period. Finally, Cardinal Capital Management grew its holdings in Halozyme Therapeutics by 6.1% in the 3rd quarter. Cardinal Capital Management now owns 29,788 shares of the biopharmaceutical company’s stock valued at $3,289,000 after buying an additional 1,712 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HALO shares. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $99.55.

Halozyme Therapeutics Trading Up 1.2%

Shares of HALO stock opened at $130.03 on Thursday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $14.76 billion, a P/E ratio of 38.82, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The stock has a 50 day simple moving average of $112.74 and a 200 day simple moving average of $82.87. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $130.24.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 earnings per share. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 5,230 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director owned 53,609 shares in the company, valued at $5,818,720.86. The trade was a 8.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.